Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01533376 · ClinicalTrials.gov registry record · Phase 1
Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol
A Phase 1 study, sponsored by Wills Eye.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01533376 is a Phase 1 study that was terminated before completion, run by Wills Eye. The registered enrollment target is 3 participants.
The verdict
NCT01533376, a Phase 1 study, was terminated before completion, sponsored by Wills Eye.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Primary Objective: • To assess the possible utility of topical timolol in the management of port-wine mark (PWM) in Sturge-Weber syndrome in children.
Interventions
- DRUG Timolol
- DRUG Preservative free artificial tear gel.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-02 |
| Est. Completion | 2019-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01533376
The ClinicalTrials.gov registry entry for NCT01533376 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Timolol is the first listed.
NCT01533376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01533376 about?
NCT01533376 is a clinical study titled "Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol". Primary Objective: • To assess the possible utility of topical timolol in the management of port-wine mark (PWM) in Sturge-Weber syndrome in children.
What is the current status of trial NCT01533376?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2012-02. Estimated completion is 2019-02.
What interventions are being tested in trial NCT01533376?
The interventions under investigation include: Timolol (DRUG), Preservative free artificial tear gel. (DRUG).
Who is sponsoring clinical trial NCT01533376?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.